U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Piperacillin Tazobactam – Injection products
  1. Development Resources

Piperacillin Tazobactam – Injection products

Recognized Interpretive Criteria

FDA Identified Interpretive Criteria

 

Minimum Inhibitory
Concentrations

(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

SDDa

I

R

S

SDDa

I

R

Enterobacteralesb

≤8/4

-

16/4

≥32/4

≥25

-

21-24

≤20

Pseudomonas aeruginosa

≤8/4

16/4

-

≥32/4

≥23

19-22

-

≤18

Acinetobacter spp.

M100 standard is recognized

Haemophilus influenzae and parainfluenzae

M100 standard is recognized

Anaerobes

M100 standard is recognized

-

-

-

S = Susceptible; SDD=Susceptible-dose dependent; I = Intermediate; R = Resistant

a Susceptible-dose dependent breakpoints are based on a dosage regimen of 4.5 grams every 6 hours as a 3-hour infusion in patients with creatinine clearance 41-120 mL/min.

b Clinical efficacy was shown for E. coli and K. pneumoniae

Exception to the recognized standard of CLSI M100

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Other Non-Enterobacterales

 
Back to Top